ZLD.AX - Zelira Therapeutics Limited

ASX - ASX Delayed price. Currency in AUD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
30/06/2022
30/06/2021
30/06/2020
30/06/2019
Total revenue
889.874
1,541
663.316
-
-
Cost of revenue
427.147
939.054
228.222
-
-
Gross profit
462.727
601.57
435.094
-
-
Operating expenses
Research development
-
-
2,081
-
-
Selling general and administrative
5,532
6,078
4,490
1,974
1,253
Total operating expenses
11,970
14,247
10,196
7,937
4,238
Operating income or loss
-11,507
-13,645
-9,760
-7,937
-4,238
Interest expense
12.344
53.848
42.627
12.344
-
Total other income/expenses net
1,090
1,275
1,253
925.491
580.442
Income before tax
-10,465
-12,414
-8,549
-7,015
-3,568
Income tax expense
0
0
0
0
0
Income from continuing operations
-10,465
-12,414
-8,549
-7,015
-3,568
Net income
-9,956
-11,945
-8,549
-7,015
-3,568
Net income available to common shareholders
-9,956
-11,945
-8,549
-7,015
-3,568
Basic EPS
-
-1.54
-1.28
-1.45
-0.82
Diluted EPS
-
-1.54
-1.28
-1.45
-0.82
Basic average shares
-
8,042
6,633
4,848
4,314
Diluted average shares
-
8,042
6,633
4,848
4,314
EBITDA
-
-11,771
-8,032
-6,728
-4,238